Treatment of advanced ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference44 articles.
1. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma;Omura;Cancer,1983
2. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study;Omura;Cancer,1986
3. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma;Neijt;Lancet,1984
4. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian cancer;Bertelsen;Gynecol. Oncol.,1987
5. Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer;Gynecol. Oncol.,1992
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer;International Journal of Molecular Sciences;2022-09-10
2. Efficacy of weekly paclitaxel for the treatment of advanced ovarian cancer;Medicine;2020-06-19
3. Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice;Pharmaceutical Research;2019-06-24
4. Interactions of cyclodextrins and their derivatives with toxic organophosphorus compounds;Beilstein Journal of Organic Chemistry;2016-02-05
5. Expression of BAF57 in ovarian cancer cells and drug sensitivity;Cancer Science;2015-02-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3